Intra-Cellular Therapies Inc.: Lumateperone’s market growth in the significant bipolar depression segment & other major drivers
Intra-Cellular Therapies, during their fourth quarter and full-year 2023 earnings, expressed a positive outlook based on strong and consistent...
Intra-Cellular Therapies Inc.: Initiation Of Coverage - 6 Major Drivers
This is our first report on biopharma major, Intra-Cellular Therapies. The company reported solid progress in its Q4 and FY2023 results, marking a...
Upgrading Staples and Health Care to Market Weight; Shift to Value; Failed Breakouts for ARKK, IPO
Shifting exposure toward value and defensives. Upgrading Consumer Staples $XLP and Health Care $XLV to market weight. $ARKK and $IPO with bearish...
S&P 500, Nasdaq 100 Testing Key Resistance Levels; Pause Likely; Buying Biotech
$SPX is testing important resistance in the 4165-4180 area, the same resistance level we were monitoring in early June before the market tumbled 13...
U.S. Equity Strategy: Bullish Outlook Intact
The action we are seeing in broad indexes, Sectors, and in market dynamics continues to support our overall bullish outlook. Continue to buy dips.
No more insights